The Roundhill S&P 500 Target 10 Managed Distribution ETF (TPAY) delivers a 10% annual distribution while maintaining full exposure to the S&P 500, using FLEX options instead of covered calls. This approach allows TPAY to keep significant cash reserves to support monthly payouts, which are largely treated as return of capital for tax deferral. However, TPAY charges a higher 0.49% expense ratio and has shown slightly lower returns than the SPY ETF, reflecting the cost of its managed distribution strategy. TPAY suits investors seeking predictable income, such as retirees, but may be less attractive for those reinvesting distributions due to fees and complexity.
The Roundhill S&P 500 Target 10 Managed Distribution ETF (TPAY) offers a 10% annual distribution with full S&P 500 exposure. For readers following US stocks on Pluang, here is the market snapshot as of Sep 15, 2026 03:11 WIB: out of 150 priced US stocks, 78 rose and 72 fell. Notable movers include MRVL at USD 219.89 with a -6.87% change, AMAT at USD 425.50 with a -6.79% change, and ACN at USD 194.68 with a +5.86% change.
Vereigen Media's Verified Content Engagement (VCE) solution won Gold at the 2026 TITAN Business Awards for improving B2B lead quality through first-party data, human verification, and engagement validation. This approach helps marketing teams deliver...
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...
Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...
On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at pr...
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
